Amanote Research

Amanote Research

    RegisterSign In

Right to Try Investigational Treatments or Not, a Clear Strategy Is Critical…

Expert Opinion on Orphan Drugs - United Kingdom
doi 10.1080/21678707.2016.1215908
Full Text
Open PDF
Abstract

Available in full text

Categories
ToxicologyPharmaceuticsPharmacologyHealth Policy
Date

August 8, 2016

Authors
Tom Watson
Publisher

Informa UK Limited


Related search

The Federal ‘Right to Try’ Act: An Answer to New Treatments During Terminal Illness?

Journal of the Advanced Practitioner in Oncology
2017English

Assessment of the Right-To-Try Law

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Now You Can't Afford Not to Try PDO.

Chemical and Engineering News
Chemical Engineering
2000English

To Educate or Not to Educate Is Not the Question

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1981English

New Venture Entry Strategy: To Pioneer or Not to Pioneer.

Academy of Management Proceedings
1997English

Is It or Is It Not a Pathogenic Mutation? Is It or Is It Not the Podocyte?

Journal of Nephropathology
Nephrology
2012English

To DAPSA or Not to DAPSA? That Is Not the Question

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

Plasmid Segregation: Birds of a Feather Try Not to Flock Together

Journal of Bacteriology
MicrobiologyMolecular Biology
2009English

To Biopsy, or Not to Biopsy: Is There Really a Question?

Annals of Surgical Oncology
OncologySurgery
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy